Connor, Clark & Lunn Investment Management (CC&L)’s Clearside Biomedical CLSD Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,694	Closed	-$38.9K	–	1420
2024 Q1	$38.9K	Buy	+1,694	New	+$36.5K	﹤0.01%	1490
2023 Q3	–	Sell	-1,037	Closed	-$17.4K	–	1386
2023 Q2	$17.4K	Sell	1,037 -2,549	-71%	-$43.9K	﹤0.01%	1286
2023 Q1	$55.9K	Sell	3,586 -216	-6%	-$4.2K	﹤0.01%	1187
2022 Q4	$63.9K	Sell	3,802 -676	-15%	-$12.2K	﹤0.01%	1142
2022 Q3	$76K	Buy	4,478 +1,143	+34%	+$25K	﹤0.01%	1050
2022 Q2	$74K	Sell	3,335 -1,948	-37%	-$47.3K	﹤0.01%	1000
2022 Q1	$181K	Buy	+5,283	New	+$158K	﹤0.01%	951

Other funds holding CLSD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CLSD Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Clearside Biomedical (CLSD) in Q2 2024, closing a stake of 1,694 shares — an estimated $38.9K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CLSD in Q1 2022 and held it in 7 quarters. The position peaked at $181K in Q1 2022. 47 funds tracked by Wall St. Rank hold CLSD as of Q2 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Clearside Biomedical position as of Q2 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 1,694 Clearside Biomedical shares in Q2 2024, an estimated $38.9K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Clearside Biomedical in Q1 2022 and held it in 7 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Clearside Biomedical position peaked at $181K in Q1 2022.
47 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.